Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis
- 1 June 2021
- journal article
- review article
- Published by Elsevier in Cancer Treatment Reviews
- Vol. 97, 102205
Abstract
No abstract availableKeywords
Funding Information
- European Commission
- Novartis
- Ministero della Salute
- Roche
- Pfizer
- Meso Scale Diagnostics
This publication has 41 references indexed in Scilit:
- The genomic and transcriptomic architecture of 2,000 breast tumours reveals novel subgroupsNature, 2012
- Survival of breast cancer patients with meningeal carcinomatosisAnnals of Oncology, 2010
- The molecular underpinning of lobular histological growth pattern: a genome‐wide transcriptomic analysis of invasive lobular carcinomas and grade‐ and molecular subtype‐matched invasive ductal carcinomas of no special typeThe Journal of Pathology, 2009
- Outcome Prediction for Estrogen Receptor-Positive Breast Cancer Based on Postneoadjuvant Endocrine Therapy Tumor CharacteristicsJNCI: Journal of the National Cancer Institute, 2008
- Distinct Clinical and Prognostic Features of Infiltrating Lobular Carcinoma of the Breast: Combined Results of 15 International Breast Cancer Study Group Clinical TrialsJournal of Clinical Oncology, 2008
- Invasive lobular carcinoma of the breast: Response to hormonal therapy and outcomesEuropean Journal of Cancer, 2008
- Advanced methods in meta‐analysis: multivariate approach and meta‐regressionStatistics in Medicine, 2002
- A comparison of methods to detect publication bias in meta‐analysisStatistics in Medicine, 2001
- Prognosis in Infiltrating Lobular CarcinomaAmerican Journal of Surgical Pathology, 1990
- Invasive lobular carcinoma of the breast: incidence and variantsHistopathology, 1979